As quoted in the press release:
“I am pleased that Dr. Sanyal has joined Revive to assist with advancing the research and clinical development of our cannabinoid-based research initiatives targeting liver diseases,” said Craig Leon, Chief Executive Officer of Revive. “Dr. Sanyal will be valuable in guiding our liver diseases product pipeline in a number of indications including liver cirrhosis, non-alcoholic steatohepatitis and non-alcoholic fatty liver disease.”
“I look forward to working with Revive Therapeutics on the broad areas of hepatic inflammation, fibrosis and cirrhosis particularly in the context of non-alcoholic fatty liver disease. I am particularly pleased to be working on the role of the cannabinoid system and non-alcoholic fatty liver disease, two areas of long standing research interest for me,” said Dr. Arun Sanyal.